Viatris said on Monday it would pay up to $335 million over nine years as part of a nationwide settlement to resolve opioid-related claims against the drugmaker. Shares of the Pennsylvania-based company, formed by the merger of Mylan and Pfizer’s …
Source: Claims Journal